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A growing number of epigenome-wide association studies have demonstrated a role for DNA methyl-
ation in the brain in Alzheimer’s disease. With the aim of exploring peripheral biomarker potential, we
have examined DNA methylation patterns in whole blood collected from 284 individuals in the Add-
NeuroMed study, which included 89 nondemented controls, 86 patients with Alzheimer’s disease, and
109 individuals with mild cognitive impairment, including 38 individuals who progressed to Alzheimer’s
disease within 1 year. We identified significant differentially methylated regions, including 12 adjacent
hypermethylated probes in the HOXB6 gene in Alzheimer’s disease, which we validated using pyrose-
quencing. Using weighted gene correlation network analysis, we identified comethylated modules of
genes that were associated with key variables such as APOE genotype and diagnosis. In summary, this
study represents the first large-scale epigenome-wide association study of Alzheimer’s disease and mild
cognitive impairment using blood. We highlight the differences in various loci and pathways in early
disease, suggesting that these patterns relate to cognitive decline at an early stage.
 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).dical School, RILD Building Level 4, Royal Devon and Exeter Hospital, Barrack Rd, Exeter, EX2 5DW. UK. Tel.: 01392
.
er Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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With an increasingly aging population the prevalence of de-
mentia is expected to almost double in the coming 20 years, with
Alzheimer’s disease (AD) being the greatest contributor. AD pre-
sents itself as a heterogeneous, multifaceted disease, and this
complexity is reflected in the challenges researchers face in eluci-
dating the exact mechanisms underlying this disorder. A number of
genome-wide association studies (GWAS) have identified suscep-
tibility loci associated with the more common, sporadic form of AD
(Lambert et al., 2013). However, these do not account fully for dis-
ease risk, and the exact processes involved in the development and
progression of this neurodegenerative disorder remain unknown.
A growing number of studies have investigated the role of
epigenetic mechanisms in the etiology and progression of AD.
Epigenetic mechanisms refer to the reversible regulation of gene
expression that occurs independently of the underlying DNA
sequence. One such mechanism is DNA methylation, which in-
volves the addition of a methyl group to an unmodified base, most
commonly cytosine (yielding 5-methylcytosine: 5mC), and plays a
critical role in the regulation of gene expression (Maunakea et al.,
2013; Varley et al., 2013; Ziller et al., 2013). Recently, numerous
epigenome-wide association studies (EWAS) have explored DNA
methylomic variation in postmortem human brain tissue from AD
patients and elderly controls and have highlighted a number of
loci that show robust differences in DNA methylation in the cortex
across independent cohorts (Altuna et al., 2019; De Jager et al.,
2014; Gasparoni et al., 2018; Lardenoije et al., 2019; Lunnon
et al., 2014; Smith et al., 2018, 2019, 2020; Watson et al., 2016).
There is communication between the brain and the blood, espe-
cially in disease. In recent years, several studies have identified
transcriptomic (Booij et al., 2011; Fehlbaum-Beurdeley et al., 2012;
Lunnon et al., 2012, 2013, 2017; Rye et al., 2011) or proteomic (Hye
et al., 2006; O’Bryant et al., 2010, 2011, 2016) alterations in the
blood early in the disease and these signatures have been used for
identifying novel dysfunctional pathways and biomarkers in the
blood. Although valuable, the use of systemic gene expression or
protein markers for this purpose still yields some pitfalls due to
the dynamic nature of gene and protein expression. For example,
sampling methods can significantly alter the expression levels by
inducing ex vivo mRNA expression (Asare et al., 2008; Thach et al.,
2003). Similarly, differences in processing methods between re-
searchers (e.g., handling methods, sample processing methods)
can affect the quality of mRNA and protein and impinge on
downstream analyses (Vartanian et al., 2009; Zhao et al., 2012).
DNA methylation levels are reported to be more stable than mRNA
levels (Paziewska et al., 2014) and as such studying this in AD
blood could be more informative of important biological pathways
specifically altered in disease. To date, most blood DNA methyl-
ation studies have focused on specifically investigating candidate
genes (da Silva et al., 2014; Furuya et al., 2012b,a; Wang et al.,
2008). Four EWAS of AD blood have been published so far,
which have identified a number of disease-associated loci. How-
ever, these studies used a limited set of (nondemented) samples
and/or did not include any individuals with mild cognitive
impairment (MCI) (Kobayashi et al., 2016; Lardenoije et al., 2019;
Lunnon et al., 2014; Madrid et al., 2018).
To understand changes in the blood related to the development
and progression of AD, it is important to include MCI individuals in
addition to AD patients and controls. Often viewed as an early stage
of AD, MCI is characterized by memory and other cognitive com-
plaints and impairment, although these have no significant impact
at this stage on daily living, as is seen in AD (Petersen et al., 1999).
Although individuals with MCI may remain stable over time or
develop another neurodegenerative disorder, MCI subjects,particularly those with amnestic MCI (aMCI), are at an increased
risk of progressing to AD (Jicha et al., 2006). In these cases, the early
clinical symptoms reflect the underlying pathological changes
related to AD that occur years before the disease fully manifests
(Hardy, 1997; Jack et al., 2010). Previous research has shown that
disease-related changes in gene expression can be detected in pe-
ripheral blood from individuals with MCI and AD, with results
indicating that some peripheral differences in AD can be detected in
MCI subjects (Lunnon et al., 2012). Taken together, the identification
of blood methylation patterns related to MCI and AD is of great
interest, as it may increase our understanding of peripheral, as well
as central changes that occur early in the disease.
In the current study, we have generated genome-wide DNA
methylation data from well-characterized control, MCI and AD
subjects with detailed demographic, clinical, neuroimaging, and
transcriptomic data previously collected. We have used this dataset
to identify differentially methylated loci and epigenetic differences
in specific biological processes in blood, which are associated with
disease status, or future progression from MCI to AD.
2. Methods
2.1. Subjects
We analyzed a subset of 284 blood samples selected for our
study from the larger AddNeuroMed cohort on the basis of addi-
tional phenotypic information being available, including genomic
(Furney et al., 2011b), transcriptomic (Lunnon et al., 2012, 2013),
and magnetic resonance imaging (MRI) data (Furney et al., 2011a,b;
Westman et al., 2011). The cross-European AddNeuroMed study is
aimed at the identification of biomarkers for AD (Lovestone et al.,
2007, 2009) and consists of 6 sites across Europe (Kuopio,
Finland; qódz, Poland; London, United Kingdom; Perugia, Italy;
Thessaloniki, Greece; Toulouse, France). Informed consent was
obtained from each participant according to the Declaration of
Helsinki, and ethical approval was obtained at each site. All sites
followed standardized procedures.
Within our subset, the subjectswere classified into one of 3 groups
according to their status at sample collection: AD (n ¼ 86), MCI (n ¼
109), or elderly control (CTL; n ¼ 89). The diagnosis of AD was made
according to the National Institute of Neurological and Communica-
tive Disorders and Stroke and the Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) criteria (McKhann et al.,
1984), and the fourth edition of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) (del Barrio, 2004). Subjects in
theMCI groupweremainly recruited frommemory clinics and scored
0.5 on the total Clinical Dementia Rating Scale (CDR) or 0.5 or 1 on the
memory category of the CDR (Morris, 1993). All MCI individuals re-
ported memory problems but showed no significant impairment in
daily living according to Petersen’s criteria of MCI (Petersen et al.,
1999). Further details are provided elsewhere (Liu et al., 2011). A
subset of MCI subjects progressed to ADwithin 1 year of the baseline
measurement (MCI-AD, n ¼ 38), while others remained stable (MCI-
MCI, n ¼ 67). A subset of 4 MCI subjects converted to AD at an un-
known time after baseline collection and were excluded from any
conversion analysis. Elderly CTLswere defined as showing no signs of
cognitive impairment. Subjects were excluded from this study if they
had any other significant psychiatric or neurological illness, were
younger than 65 years of age, or were not white Caucasian. MRI data
were collected for 213 individuals as described previously (Simmons
et al., 2011). To obtain demographic information and medical data,
semistructured interviewswere carried out for all subjects. A number
of neuropsychological assessments were also performed, including
the mini-mental state examination (MMSE) (Folstein et al., 1975). An
overview of individuals included in this study can be found in Table 1.
Table 1
Cohort demographics
Control MCI AD
MCI-MCI MCI-AD
N 89 67 42a 86
Gender (M/F) 34/55 34/33 16/26 30/56
Age (mean  SD) 73.8  5.3 75.1  5.6 76.3  5.3 76.8  5.6
MMSE (mean  SD) 29  1.2 27.3  1.7 26.3  2.2 20.8  4.5
Center (N)
Kuopio (Finland) 22 17 16 27
qódz (Poland) 13 5 1 8
London (United Kingdom) 22 6 3 7
Perugia (Italy) 19 19 14 23
Thessaloniki (Greece) 4 16 5 16
Toulouse (France) 9 4 3 5
Subject characteristics of the 284 samples that passed QC. Shown are sample numbers (N), sex (males [M]/females [F]), mean age ( standard deviation [SD]), mean mini-
mental state examination (MMSE)  SD, and sample numbers per source (Center). Of the 109 mild cognitive impairment (MCI) subjects, 67 remained MCI-stable (MCI-
MCI) over the 1 year after sample collections, while 42 converted to AD (MCI-AD), with 38 converting within 1 year of sample collections.
a Four MCI-AD subjects were excluded from the analysis of MCI to AD conversion (but included in the ANOVA analysis of baseline diagnosis), as the exact time of conversion
was not known. All individuals used in this study were white Caucasian.
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DNAwas extracted from the blood samples collected at baseline
as described by Furney et al. (2011). The DNA was tested for
degradation and purity. 500 ng DNA from each sample was sodium
bisulfiteetreated using the Zymo EZ-96 DNAmethylation kit (Zymo
Research, CA, USA) according to the manufacturer’s standard pro-
tocol. Samples were assessed using the Illumina Infinium Human
Methylation 450K BeadChip array (450K array; Illumina, CA, USA)
using an Illumina HiScan System (Illumina, CA, USA). All samples
were assigned a unique code for the purpose of the experiment and
randomized with respect to sex, center, and disease status to avoid
batch effects, and processed in batches of 4 BeadChips.
Raw intensity data files were imported into the R statistical
environment (version 3.5.2) (R Core Team, 2018) using the wateR-
melon (Pidsley et al., 2013) package as a methylumi object. Data
quality control (QC) and preprocessing was carried out using the
packages wateRmelon and minfi (Aryee et al., 2014). Initial QC
checks on the data included labeling checks via sex and genetical
identity, and the removal of cross-hybridizing probes, probes
located on the sex chromosomes, and probes containing a single
nucleotide polymorphism in the probe sequence or within 10 bp
(Chen et al., 2013; Price et al., 2013). The p-filter function was
applied, followed by the outlyx function within the wateRmelon
package, with none of the 284 samples identified as outliers.
Quantile normalization was then carried out using the dasen
function within wateRmelon, with 401,266 probes taken forward
for analysis. Blood cell type proportions were calculated using the
Houseman referenceebased method (Houseman et al., 2012). DNA
methylation data can be found on GEO under the accession number
GSE144858.
Before we identified differentially methylated positions (DMPs)
associated with diagnosis, we first regressed out the effect of spe-
cific covariates that correlatedwith the first 3 principal components
of the normalized data (Supplementary Fig. 1), with these variables
being age, sex, blood cell type proportion (CD4 and CD8 T lym-
phocytes, natural killer cells, B cells, monocytes, granulocytes), and
bisulfite conversion batch. An analysis of variance (ANOVA) was
then performed on the residuals from the linear regression, to test
for DNA methylation differences across all 3 groups. A post-hoc
Tukey’s honest significant difference (HSD) test (Tukey, 1949) was
applied to the results to compare methylation levels between each
of the 3 diagnostic groups at baseline (CTL, MCI, AD). For the pur-
pose of these analyses, the MCI group included both MCI-MCI and
MCI-AD as both groups were classified as MCI at baseline, whichwas the time point when blood sampling occurred. To identify
differentially methylated regions (DMRs), which represent areas of
the DNA containing multiple adjacent DMPs, we used the DMPs
from both the ANOVA and the individual between group Tukey’s
tests and applied the comb-p module (Pedersen et al., 2012) in
Python (version 2.7.5) (Rossum and Boer, 1991), assessing regions of
1000 base pairs, with a p-value threshold of p < 0.01. We selected
only regions containing 2 probes, and that had a multiple testing-
corrected p < 0.05, which was corrected using the Sidák method
(Sidák, 1967). To identify DMPs and DMRs relating to the future
conversion from MCI to AD we performed an analysis comparing
the MCI-MCI subjects and the MCI-AD subjects, by first regressing
out age, sex, blood cell type proportion, batch, and baseline MMSE
score. Baseline MMSE score was included as a covariate as we
observed a small, but significant difference in baseline MMSE be-
tween the MCI-MCI and MCI-AD groups. We then used a linear
regression to compare the 2 groups and performed comb-p analysis
as described above. Quantile-quantile (QQ)-plots of the p-values
from both the ANOVA and linear regression can be found in
Supplementary Fig. 2.
2.3. Generation of weighted gene correlation networks
In order to identify clusters, or “modules”, of highly comethy-
lated sites in the genome, we made use of the R package for
weighted gene correlation network analysis (WGCNA) (Langfelder
and Horvath, 2008). The hypothesis underlying this method is
that genes that highly co-vary, share the same underlying biological
processes. Prior to creating the modules, all nonvariable probes
(variance < median variance) were first removed from the
normalized data, leaving 200,633 probes for analysis. Samples were
then clustered based on their Euclidean distance, and clustering
dendrograms were visually inspected to identify outlier samples,
which were not detected. Network construction and module
detection was then performed in a block-wise manner and con-
structed irrespective of the direction of correlation between probes
(unsigned). The connection strength between 2 probes was
weighted using a soft threshold value of 9 in the baseline group
analysis and 8 in the comparison of MCI converters to MCI non-
converters, which emphasizes high correlations over low correla-
tions. The soft threshold values were selected using the
pickSoftThreshold function within the WGCNA package. In the
resulting modules, each module is identified by an arbitrarily
assigned color, and the gray module is disregarded from further
analyses as it contains unassigned probes. Module eigengenes
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component across probes assigned to each module. The ME is a
single value for each sample and represents the shared methylation
profile of the module. Modules were generated twice: once for the
baseline group analysis, which compared CTL to MCI to AD, and
once for the conversion analysis using only the subset of MCI-MCI
and MCI-AD samples.
2.4. Association of modules to traits of interest
Covariates (age, sex, blood cell type proportions, and batch
number) were regressed out from the MEs, and extreme outliers
(exceeding >5 standard deviations) were removed. Modules were
then associated with baseline diagnosis groups and traits of interest
by performing pairwise Pearson or Spearman correlations for
continuous or ordinal variables, respectively. Correlations were
performed using dummy variables of baseline diagnosis categories
to investigate all permutations of comparisons (i.e., CTL versus MCI,
CTL versus AD, andMCI versus AD), with the group not used in each
comparison set to NA. Additional traits of interest included number
of education years, number of APOE ε4 alleles, MMSE score, and the
following structural MRI measurements: left, right, and total en-
torhinal cortex volume (LEV, REV, and TEV, respectively), left, right,
and total hippocampal volume (LHV, RHV, and THV, respectively),
ventricular volume (VV), and whole brain volume (WBV). Similarly,
regression of the same covariates (with the addition of baseline
MMSE score) and outlier removal was also performed for MEs
generated from the MCI-MCI and MCI-AD samples. The residuals
from this regression were then used to run a linear regression,
comparing nonconverters to converters.
2.5. Module membership and probe significance
For each of the modules showing significant (p < 0.05) associ-
ations with one of the 3 baseline groups, conversion to AD, or traits
of interest, we calculated the module membership (MM) and probe
significance (PS). MM was calculated as the Pearson correlation
between the methylation value of each probe and the ME values,
representing the strength of association between a probe and the
module it belongs to. PS represents the strength of the correlation
between a probe’s methylation value and the diagnosis or trait of
interest, as performed by Pearson correlations for continuous traits,
and Spearman correlations for ordinal traits or diagnostic groups.
We correlated and plotted MM to PS for modules of interest and
focused on those that showed significant positive correlations (i.e.,
r > 0, p < 0.05), which would indicate that probes more integral to
the module are mainly driving the association with the trait of in-
terest. Underlying biological processes and pathways were then
examined for the modules selected, using Gene Ontology (GO) and
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
enrichment analyses. For modules containing a large number of
probes (>10,000), we performed these pathway analyses on the
probes that were central to the module (i.e., core probes). We set
this threshold at 15%, thus selecting the top 15% of probes with the
highest MM. Analyses were performed using the missMethyl pack-
age (Phipson et al., 2015), taking into account the differing number
of probes covering each gene on the array.
2.6. Analysis of gene expression data and association with
methylation data
Normalized gene expression data from Illumina Human HT-12
v3 Expression BeadChip arrays (HT-12 arrays) was obtained from
a previous study by Lunnon et al. (2012), for 237 individuals
included in the current study. Expression data for all genescontaining DMRs identified in this study were extracted for analysis
if available. For genes nominated from the diagnostic category
analysis (CTL, MCI, AD), the covariates of age, sex, and cell type
proportions (estimated using Houseman’s referenceebased
method) were regressed out of the expression data and an
ANOVA and subsequent Tukey’s HSD were then performed on the
residuals of the regression to identify diagnostic category differ-
ences in expression levels of genes containing DMRs. For genes that
contained DMRs associated with the progression to AD, only the
MCI-MCI and MCI-AD samples were analyzed, with age, sex, cell
type proportions, and baseline MMSE score regressed out of the
expression data, with a subsequent linear regression analysis per-
formed to assess gene expression differences betweenMCI-MCI and
MCI-AD individuals in DMR genes.
Next, methylation values within a DMR were correlated to gene
expression values of an annotated gene. Methylation values that had
previously been corrected for covariates (i.e., residuals) were
extracted for 450K array probes located within each DMR based on
genomic location of the DMRs. Pairwise Pearson correlations were
then performed between the covariate-adjusted gene expression
levels and covariate-adjusted methylation values, for individual
450K probes within a DMR. We also performed correlations of gene
expression and mean methylation levels from all 450K probes in the
DMR. To determine whether the association between gene expres-
sion andmethylation differed between CTL and individuals withMCI
or AD, ANOVAs were performed on gene expression levels which
included an interaction term between methylation and baseline
diagnostic groups (i.e., expression ~ methylation*group). This was
performed on the probe most significantly associated with the dis-
ease for each DMR, and the mean methylation value in the DMR.
Similar analyseswere performed on theMCI-MCI andMCI-AD subset
of individuals, for DMRs associated with progression to AD.2.7. Validation of the HOXB6 differentially methylated region using
pyrosequencing
For the purpose of validating our findings, we designed a pyro-
sequencing assay to quantify DNA methylation at the most signifi-
cant sites (cg17179862 and cg03803541) within the HOXB6 region
(chr17:46681111e46682414), which was shown to be a DMR in AD
relative to CTL. Pyrosequencing assays were designed with the
PyroMark Assay Design software 2.0 (Qiagen). In addition to the 2
CpG sites the assay was designed for, further 3 CpG sites that were
not assessed on the 450K array were also covered. Out of the original
284 samples, 264 were used for pyrosequencing. Samples were
semi-randomly selected, keeping the group sample number ratios as
equal as possible, and randomly distributing samples across plates. A
single amplicon of 303 base pairs was amplified using designed
primers, and tested for specificity (forward primer ¼
TTTTTGGTGAGGGGGGAGT, reverse primer ¼ CCTACCATCCCTCCCT-
TATCT, sequencing primer ¼ CTCTAACTATTACCCC). The level of DNA
methylation was then quantified using the Pyromark Q24 system
(Qiagen), following the standard protocol as provided by the
manufacturer and the Pyro Q24 CpG 2.0.6.20 software.
Pyrosequencing data QCwas performed using the Pyromark Q24
software, in addition to a visual inspection of the data and signal
intensities, with all 264 samples passing QC (CTL: n ¼ 83, MCI: n ¼
102, AD: n¼ 79). DNAmethylation percentages at specific CpG sites
were calculated by the software and exported to the R statistical
environment. Subsequently, an ANOVAwas performed for each CpG
site covered by the assay, as well as the average methylation value
across the region. This analysis was identical to the analysis per-
formed on the 450K data, and the covariates of age, sex, cell type
proportion, and batch were included.
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3.1. Identification of differentially methylated loci in mild cognitive
impairment and Alzheimer’s disease blood
The cohort characteristics are shown in Table 1. We first investi-
gated whether any individual loci showed DNA methylation differ-
ences in eitherMCI or AD relative to CTL using an ANOVAmodel after
adjusting for the covariates of age, sex, cell proportions, and batch
(Supplementary Table 1). No DMPs reached the experiment-wide
significance threshold that has been established for the 450K array
(2.4  107) (Saffari et al., 2018) with the smallest ANOVA p-value
being 5.58  106 for probe cg26146855, of which the closest tran-
scription start site is located in the TFAMP1 gene. The top 1000 most
significant probes resulting from the post-hoc Tukey’s HSD tests
comparing CTL to MCI, MCI to AD, and CTL to AD can be found in
Supplementary Tables 2, 3, and 4, respectively. In addition to
comparing methylation levels at baseline between the 3 groups, we
were also interested in identifying differences within the MCI pop-
ulation that were predictive of later progression to AD. For this
purpose, we compared the MCI-MCI group to the MCI-AD group.
While no DMPs passed the experiment-wide significance threshold,
the most significant DMP was located in the TRIM62 gene and
showed hypomethylation in converters (probe cg25342005, p ¼
1.67  106; Supplementary Table 5).
3.2. A number of significant differentially methylated regions can be
identified in mild cognitive impairment and Alzheimer’s disease
blood
We next used a sliding window approach to identify the regions
spanning multiple adjacent DMPs that were significantly different
inMCI and AD.We found 4 DMRs associated with differences acrossTable 2
Differentially methylated regions in blood
Gene Position Gene feature
A. ANOVA: CTL versus
MCI versus AD
HOXB-AS3; HOXB6 chr 17: 46681111 - 46682414 nc_intronþnc_exon;
intronþexonþutr5
MOV10L1 chr 22: 50528179 - 50528753 TSSþintronþutr5þcd
TSSþexonþutr5
CBFA2T3 chr 16: 88937216 - 88937798 Intergenic
TPTEP2-CSNK1E chr 22: 38714166 - 38714467 intronþutr5
B. CTL vs. AD
HOXB-AS3; HOXB6 chr 17: 46681111 - 46682414 nc_intronþnc_exon;
intronþexonþutr5
Gene Position Gene feature
C. MCI-MCI vs. MCI-AD
CHKB-CPT1B; CPT1B;
CHKB
chr 22: 51016501 - 51017433 nc_intron; TSSþintro
exonþutr5; exonþut
SMC1B; RIBC2 chr 22: 45809319 - 45810044 TSSþintronþutr5þcd
intronþutr5þcds
TMEM184A chr 7: 1595602 - 1596261 TSSþintronþexonþu
KCNAB3 chr 17: 7832680 - 7833238 TSSþcds
GABBR1 chr 6: 29599012 - 29599391 intronþexonþutr5; i
cds
FIGN chr 2: 164204628 - 164205344 Intergenic
PRDM1 chr 6: 106546704 - 106546825 TSSþexonþutr5; intr
FLJ37453 chr 1: 16163555 - 16164123 nc_intron
OR56A3; TRIM5 chr 11: 5959658 - 5960214 Intergenic
Differentially methylated regions (DMRs) in a comparison of control (CTL), mild cognitive
(A) the overall three group (ANOVA) comparison, the post-hoc (B) CTL versus AD compar
Displayed for each region is the UCSC gene name, chromosomal position (genome build 37
untranslated region; cds ¼ coding sequence), number of probes in region (n), p-value anthe 3 baseline groups (CTL, MCI, and AD) (Table 2A). A 10-probe
DMR of 574 bp was identified in MOV10L1 (Fig. 1A), as well as a 5-
probe (582 bp) intergenic DMR annotated to CBFA2T3 (Fig. 1B),
with probes in both DMRs generally showing hypermethylation in
MCI samples, with levels in AD samples similar to CTL. An 8-probe
DMRof 301 bpwas found in the readthrough transcription region of
TPTEP2-CSNK1E, which appeared to be mainly driven by hyper-
methylation in the MCI group (Fig. 1C).
One of the 4 identified DMRswas driven by a difference between
the CTL and AD groups (Table 2B); we identified a 1303 bp DMR in
the HOXB6 gene, containing 12 probes (Figs. 1D and 2). Each of the
12 probes showed hypermethylation in AD.
In our analysis of MCI conversion to AD, we identified 9 signif-
icant DMRs (Table 2C; Fig. 3). We found DMRs showing decreased
methylation in MCI-AD converters relative to MCI-MCI non-
converters in the genes CPT1B and CHKB (932 bp; 14 probes)
(Fig. 3A), TMEM184 A (659 bp; 6 probes) (Fig. 3B), KCNAB3 (558 bp; 7
probes) (Fig. 3C), GABBR1 (379 bp; 10 probes) (Fig. 3D), PRDM1
(121 bp; 5 probes) (Fig. 3E), FLJ37453 (568 bp; 6 probes) (Fig. 3F),
and OR56A3 and TRIM5 (556 bp; 5 probes) (Fig. 3G). Hyper-
methylation in MCI-AD converters relative to MCI-MCI non-
converters was seen in 2 DMRs located in the genes SMC1B and
RIBC2 (725 bp; 15 probes) (Fig. 3H), and an intergenic region near
the gene FIGN (716 bp; 6 probes) (Fig. 3I).
3.3. Validation of the Alzheimer’s diseaseeassociated differentially
methylated region in HOXB6 by pyrosequencing
Interestingly, differential DNA methylation at the most signifi-
cant locus within the HOXB6 DMR (cg17179862) has been previ-
ously reported in AD hippocampus (Altuna et al., 2019). To further
explore AD-associated hypermethylation in this gene, we used
pyrosequencing to validate our HOXB6 DMR, covering 2 CpG sitesn p-value Sidák-P Average methylation %
CTL MCI AD
TSSþ 12 2.79E-14 8.58E-12 56.59 58.79 60.81
s; 10 2.03E-07 1.42E-04 68.38 70.18 68.23
5 2.61E-07 1.80E-04 42.57 44.66 42.34
8 1.87E-06 2.49E-03 41.21 42.29 41.69
TSSþ 12 3.36E-16 1.03E-13 56.59 58.79 60.81
n p-value Sidák-P Average methylation %
MCI-MCI MCI-AD
nþ
r3
14 2.05E-14 8.84E-12 64.92 61.26
s; TSSþ 15 8.26E-09 4.57E-06 24.62 26.62
tr5 6 2.41E-08 1.47E-05 45.33 43.31
7 8.11E-08 5.83E-05 80.31 76.73
ntronþ 10 9.72E-08 1.03E-04 63.80 61.48
6 3.58E-07 2.01E-04 52.84 56.10
on 5 1.04E-07 3.45E-04 62.01 58.89
6 5.92E-07 4.18E-04 29.67 27.34
5 9.68E-07 6.98E-04 81.17 77.54
impairment (MCI), and Alzheimer's disease (AD) blood samples. Shown are DMRs for
ison, and (C) the MCI-stable (MCI-MCI) versus MCI-converter (MCI-AD) comparison.
), gene feature (TSS¼ transcription start site; utr5¼ 50 untranslated region; utr3¼ 30
d multiple testing-corrected p-value (Sidák-P), and average beta per group.
Fig. 1. Differentially methylated regions (DMRs) in a comparison of baseline diagnosis of mild cognitive impairment and Alzheimer's disease relative to controls. DMRs shown are
located in or near the genes MOV10L1 (A), CBFA2T3 (B), TPTEP2-CSNK1E (C), and HOXB6 (D). Displayed for each DMR are the methylation levels of individual probes located within
the DMR, ordered by genomic location. Methylation values have been corrected for covariates age, sex, cell type proportion, and batch.
J.A.Y. Roubroeks et al. / Neurobiology of Aging 95 (2020) 26e45 31on the array (cg17179862, cg03803541) as well as 3 neighboring
CpG sites that were not covered by the 450K array (chr17:46681421,
chr17:46681394, and chr17:46681383). We found significantdifferences between groups at all 5 CpG sites (Supplementary
Table 6, Fig. 4A), and when averaged over the full 5 probes
(Fig. 4B), demonstrating hypermethylation in AD samples relative
Fig. 1. (continued).
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array and pyrosequencing was similar for both cg03803541 (Fig. 4C)
and cg17179862 (Fig. 4D), with a significant correlation of the
methylation values estimated by the 2 technologies for both
cg03803541 (Fig. 4E: r ¼ 0.957, p ¼ 2.69  10142) and cg17179862
(Fig. 4F: r ¼ 0.934, p ¼ 5.03  1068).3.4. Transcriptional differences in genes containing differentially
methylated regions
To explore the relationship between DNA methylation and
expression, we first assessedwhether the expression levels of genes
containing the 4 baseline diagnosis-associated DMRs or the 9
Fig. 2. The HOXB6 DMRs, shown to be altered in Alzheimer's disease (AD) relative to controls (CTL). The region spanned by the DMRs is highlighted in red, and genomic location and
UCSC gene annotations are shown, in addition to a mini-Manhattan plot of the p-values of probes within and neighboring the DMR, p-values related to changes in AD relative to CTL
are shown in orange, mild cognitive impairment (MCI) relative to CTL in green, and AD relative to MCI in purple. The bottom panel shows relative methylation levels across the
region, with methylation in AD in orange, MCI in green, and CTL in blue. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version
of this article.)
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sion data were only available for 2 of the 6 genes we identified as
containing DMRs in the baseline group analysis (HOXB6, and
CSNK1E associated with the readthrough transcription region of
TPTEP2-CSNK1E) (Supplementary Table 7). Of these 2 genes,
CSNK1E, which had shown increased DNA methylation in MCI
samples, also showed a significant difference in gene expression
between groups (F ¼ 15.94, p ¼ 3.25  107). More specifically, we
observed significantly increased mRNA expression in both MCI and
AD subjects relative to control (Tukey’s p ¼ 1.46  107 and p ¼
0.003, respectively, Supplementary Fig. 3A). Although there was
significantly higher gene expression and DNA methylation (across
the DMR), there was no correlation of expression and methylation
across all samples, or whenwe performed correlations separately in
the 3 diagnostic groups (Supplementary Fig. 3C, Supplementary
Table 8). Although we did not observe any significant differences
in gene expression for HOXB6 (Supplementary Fig. 4A), we did find
a correlation of expression and methylation when performingcorrelations in the AD group only (r ¼ -0.24, p ¼ 0.041)
(Supplementary Fig. 4C, Supplementary Table 8).
Expression data were also available for 5 of the 9 significant
DMRs we identified in our analysis of progression from MCI to AD
(GABBR1, PRDM1, FLJ37453, TRIM5, and CPT1B/CHKB). The CPT1B/
CHKB DMR was covered by 3 probes on the gene expression
microarray, one probe measuring CPT1B expression and 2 probes
measuring CHKB expression (ILMN_2331205 and ILMN_1659054).
Although none of these genes showed differential expression in
MCI subjects who progressed to AD (Supplementary Table 9),
CPT1B/CHKB showed a significant positive correlation of methyl-
ation across the DMR and CPT1B gene expression (Supplementary
Table 10). The average methylation level across the CPT1B/CHKB
DMR was significantly correlated with gene expression across all
samples (r ¼ 0.40, p ¼ 8.62  105, Supplementary Fig. 5), which
appeared to be primarily driven by a correlation observed in the
MCI-MCI samples (r ¼ 0.49, p ¼ 7.27  105) and not the MCI-AD
samples.
Fig. 3. Differentially methylated regions (DMRs) in a comparison of mild cognitive impairment (MCI) individuals who converted to Alzheimer's disease (AD) within 1 year after
baseline assessment (MCI-AD; dark green, shown on the right) and those who remained stable (MCI-MCI; light green, shown on the left). DMRs shown are located in or near the
genes CPT1B (A), TMEM184 A (B), KCNAB3 (C), GABBR1 (D), PRDM1 (E), FLJ37453 (F), OR56A3 and TRIM5 (G), SMC1B and RIBC2 (H), and FIGN (I). Displayed for each DMR are the
methylation levels of all probes (p < 0.05) within the genomic location covered by each DMR, ordered by genomic location. Methylation values have been corrected for covariates
age, sex, cell type proportion, batch, and baseline mini-mental state examination score. (For interpretation of the references to color in this figure legend, the reader is referred to
the Web version of this article.)
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impairment and Alzheimer’s disease
To identify clusters of probes that are comethylated and are
therefore hypothesized to share a common function, we performed
WGCNA and classified the entire filtered data set of 200,633 probesinto 16 modules (Fig. 5A). These modules were correlated to the
group comparisons of diagnostic status at baseline, as well as to
several other traits of interest (Fig. 5B, Supplementary Table 11),
after controlling for covariates. The brown module, which consists
of 11,794 probes, was negatively correlated with differences be-
tween CTL and MCI (r ¼ 0.16, p ¼ 2.31  102) and correlated
Fig. 3. (continued).
J.A.Y. Roubroeks et al. / Neurobiology of Aging 95 (2020) 26e4536positively with an individual’s number of education years (r ¼ 0.13,
p ¼ 3.59  102). Three more modules also showed a correlation
with MCI versus CTL; the light cyan module consisting of 133probes (r ¼ 0.18, p ¼ 1.2  102), and the yellow module which
consists of 10,635 probes (r ¼ 0.17, p ¼ 1.51  102). The yellow
module further correlates to the structural imaging variable MET
Fig. 3. (continued).
J.A.Y. Roubroeks et al. / Neurobiology of Aging 95 (2020) 26e45 37(r ¼ 0.14, p ¼ 4.26  102). The purple module (792 probes) also
correlates to MCI versus CTL (r ¼ 0.17, p ¼ 1.98  102), as well as
the majority of structural imaging variables: REV (r ¼ 0.21, p ¼3.16  103), TEV (r ¼ 0.18, p ¼ 9.85  103), MET (r ¼ 0.25, p ¼
3.22  104), VV (r ¼ -0.18, p ¼ 9.25  103), LHV (r ¼ 0.22, p ¼
1.19  103), RHV (r ¼ 0.20, p ¼ 3.31  103), THV (r ¼ 0.22, p ¼
Fig. 3. (continued).
J.A.Y. Roubroeks et al. / Neurobiology of Aging 95 (2020) 26e45381.46  103), and WBV (r ¼ 0.20, p ¼ 3.55  103). Finally, the cyan
module (280 probes) correlates to an individual’s number of APOE
ε4 alleles (r ¼ 0.14, p ¼ 1.75  102).
Subsequently, we investigated whether the probes that are in-
tegral to a specific module are also the probes that are driving the
association with the relevant diagnosis or trait. We did this by
correlating and plotting MM and PS values, and focusing on those
modules that showed positive (r> 0, p< 0.05) correlations between
MM and PS (Supplementary Table 12). Significant positiveMM to PS
correlations were found in the brown (r ¼ 0.26, p ¼ 5.93  10179),
purple (r ¼ 0.19, p ¼ 9.18  108), and yellow (r ¼ 0.25, p ¼ 6.64 
10153) modules in association with CTL versus MCI. The brown
module further showed significant positiveMM to PS correlations in
relation to education years (r ¼ 0.11, p ¼ 2.40  1032). The yellow
module displayed a positive MM to PS correlation (r ¼ 0.22, p ¼
6.4210117) in associationwithMET, and the cyanmodule showed
a positive MM to PS correlation in association with the number of
APOE ε4 alleles (r ¼ 0.20, p ¼ 6.42  104). These modules were the
primary focus of our pathway analyses. MM and PS plots for these
modules are shown in Supplementary Fig. 6; for a full overviewof all
MM and PS correlations, see Supplementary Table 12.
3.6. Functional role of modules associated with mild cognitive
impairment and Alzheimer’s disease
We sought to identify the pathways that were enriched in
modules that were affected in disease or were associated with
certain traits. For this purpose, we performed GO and KEGG
enrichment analyses, with for large (i.e., yellow and brown) mod-
ules only the core probes being used for the enrichment analyses.
Pathways related to the brown (Supplementary Fig. 7), purple,
yellow (Supplementary Fig. 8), and cyan (Supplementary Fig. 9)
modules all passed false discovery rate (FDR) multiple testing
correction. A large number of GO terms were associated with the
core of the brown module, which was related to MCI relative to CTLas well as number of education years, among which were “extra-
cellular matrix” (q ¼ 4.23  107), “channel activity” (q ¼ 3.19 
105), and “passive transmembrane transporter activity” (q¼ 3.19
105) (Supplementary Fig. 7A). Furthermore, KEGG terms related to
thismodule included “Protein digestion and absorption” (q¼ 1.06
102), “Oxytocin signaling pathway” (q ¼ 1.06  102), and
“Regulation of actin cytoskeleton” (q¼ 1.10 102) (Supplementary
Fig. 7B). The core of the yellow module showed differences related
to MCI, relative to CTL, as well as MET, and we found in our
enrichment analyses of the core probes that the top GO terms
included “leukocyte activation” (q ¼ 7.46  1013), “cell activation”
(q¼ 7.46 1013), and “immune response” (q¼ 5.841011), while
the top KEGG terms included “platelet activation” (q¼ 1.93 102),
“adrenergic signaling in cardiomyocytes” (q ¼ 1.93  102), and
“sphingolipid signaling pathway” (q¼ 2.34102) (Supplementary
Fig. 8). The purple module, which was also associated with differ-
ences related to MCI relative to CTL, was connected with one GO
term; “vesicle-mediated transport” (q ¼ 4.35  102), but no sig-
nificant KEGG terms. Finally, the cyan module, which was associ-
ated with the number of APOE ε4 alleles, was related to a number of
GO terms, including “cell activation” (q ¼ 3.07  104), “regulation
of cell adhesion” (q ¼ 4.51  104), “leukocyte activation” (q ¼
4.51  104), and “regulation of cell death” (q ¼ 8.32  104)
(Supplementary Fig. 9) and one KEGG pathway: “T cell receptor
signaling pathway” (q ¼ 3.73  102).
3.7. Investigating clusters of comethylated loci associated with
progression to Alzheimer’s disease
In addition tomodules associatedwith baseline diagnosis of MCI
and AD, we also identified 31 modules of highly comethylated loci
in the subset of MCI-MCI and MCI-AD samples (Supplementary
Fig. 10). Only one of these modules, the orange module, was
shown to be significantly associated with future progression to AD
(b ¼ -0.04, p ¼ 4.38  102; Supplementary Table 13). We then
Fig. 4. Validation of the HOXB6 differentially methylated region. DNA methylation was assessed via pyrosequencing and significant changes were found between controls and
individuals with Alzheimer's disease, but not mild cognitive impairment at all 5 CpG sites assessed (A) and when averaged over all 5 probes (B). DNA methylation patterns
quantified by the Illumina 450K array and pyrosequencing were similar for cg03803541 (C) and cg17179862 (D) and were significantly correlated (E and F, respectively).
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positive correlation (r ¼ 0.36, p ¼ 9.40  106). Following GO and
KEGG pathway analysis, we found no GO terms passing FDR mul-
tiple testing correction, but top KEGG terms included “renal cell
carcinoma” (q ¼ 1.21  102), “nonhomologous end-joining” (q ¼
2.00  102), and “ErbB signaling pathway” (q ¼ 2.00  102)
(Supplementary Fig. 11).4. Discussion
The present study, which reflects the first large-scale EWAS of
AD blood samples, identified epigenetic signatures related to AD
and MCI, as well as signatures associated with future conversion
from MCI to AD.The HOXB6 gene contained a DMR that reflected differences in
methylation in AD relative to CTL, which were validated using
pyrosequencing. HOXB6 encodes the homeobox protein B6, which
is part of a larger cluster of homeobox B genes located on chro-
mosome 17. Homeobox genes are DNA-binding proteins that have
been implicated in early body morphogenesis (Krumlauf, 1994) as
well as hematopoietic development. Specifically, HOXB6 has been
shown to be required for normal generation of granulocytes and
monocytes (Giampaolo et al., 2002). Interestingly, a recent EWAS of
AD hippocampus has shown DNA methylation differences in
cg17179862, which was the most significant probe in the DMR we
identified and validated (Altuna et al., 2019). The study by Altuna
et al. further showed that increased methylation at this locus was
positively correlated with tau burden.
Fig. 4. (continued).
J.A.Y. Roubroeks et al. / Neurobiology of Aging 95 (2020) 26e4540MOV10L1, which was associated with differences between all 3
groups, encodes an RNA helicase. This protein was shown to be
crucial for the production of Piwi-interacting RNAs (piRNAs) by
Vourekas et al. (2015). PiRNAs represent small noncoding RNAs
involved in epigenetic regulation, which can bind to PIWI proteins
and may induce gene silencing via DNA methylation (Aravin et al.,
2008; Girard et al., 2006), or RNA-cleavage (for a review, see
Luteijn and Ketting (2013)). Although initially believed to be mainly
present in germline cells, piRNAs have been shown to be stably
expressed in human blood (Yang et al., 2015) and have also been
shown to be downregulated in tumor tissue and upregulated inblood of renal carcinomas (Iliev et al., 2016). Interestingly, Watson
et al. (2016) performed an EWAS of AD superior temporal gyrus
and identified a DMR spanning 13 probes, including all ten probes
we identified in the MOV10L1 gene in the current study. Of note,
whereWatson et al. detected AD-related hypermethylation in these
10 probes, we found hypermethylation inMCI when comparedwith
AD and CTL individuals, while methylation levels of AD subjects
were not distinct from CTL individuals.
Of the 9 DMRs that were related to future conversion to AD, our
most significant region was located in CPT1B, which encodes the
protein carnitine palmitoyltransferase 1B. Differential DNA
Fig. 5. Clusters (or “modules”) of highly comethylated loci identified in the full dataset of 284 samples (A). Modules are hierarchically clustered based on calculated module
eigengenes (representative of the methylation values within each module), and the number of probes included in each module are indicated along the x-axes. The color of each
module is assigned in an arbitrary manner. (B) Correlations between module eigengenes and traits of interest, with module names shown along the y-axis. Correlation estimates are
reported, with p-values in parentheses. Spearman correlations were performed for the controls (CTL) versus Alzheimer's disease (AD) comparison, CTL versus mild cognitive
impairment (MCI) comparison, the MCI versus AD comparison, and the number of APOE-ε4 alleles (APOE #4). Pearson correlations were calculated for the number of education
years (Education_Yrs); mini mental state examination (MMSE) scores; and the following structural imaging measurements: right, left, and total entorhinal volume (REV, LEV, and
TEV, respectively); mean entorhinal thickness (MET); ventricular volume (VV); left, right and total hippocampal volume (LHV, RHV, and THV, respectively); and whole brain volume
(WBV). Modules with a correlation p-value <0.05 were selected for further analysis. (For interpretation of the references to color in this figure legend, the reader is referred to the
Web version of this article.)
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fetal cortex of patients with Down syndrome (El Hajj et al., 2016;
Kerkel et al., 2010). This is interesting as individuals with Down
syndrome often develop AD as a result of trisomy of chromosome
21, causing them to have an additional copy of the amyloid pre-
cursor protein (APP) gene. The study by El Hajj et al. (2016) iden-
tified a DMR in CPT1B consisting of 18 probes in Down syndrome
fetal cortex samples, which spanned the region discovered in the
present study. They detected hypermethylation in 13 probes in
Down syndrome, while we observed hypomethylation in those MCI
individuals who convert to AD. Kerkel et al. (2010) similarly
detected hypermethylation at one CpG site in our CPT1B DMR in
peripheral blood leukocytes of individuals with Down syndrome,
concomitant with significant overexpression of the gene. While we
observed hypomethylation of the DMR, the positive relationship
found between methylation and expression for this region was
validated in our study. Of note, overexpression of CPT1B has also
been found in blood from soldiers with post-traumatic stress dis-
order (Zhang et al., 2015), a known risk factor for developing AD
(Agís-Balboa et al., 2017; Yaffe et al., 2010). Interestingly, no overlap
was found between DMRs associated with conversion and DMRs
related to diagnosis at baseline. This may reflect limited power in
our MCI conversion analysis due to sample size or could reflect
temporal patterns of DNA methylation in the process of conversion
from MCI to AD.
In addition to DMRs, by using WGCNA and subsequent pathway
analyses we further identified biological mechanisms affected in
disease. The cyan module that was linked to the number of APOE ε4
alleles is involved in GO pathways related to the immune system,
which is interesting given that the immune system is known to be
activated in AD (Heppner et al., 2015), and as APOE ε4 is the
strongest genetic risk factor for sporadic AD (Lambert et al., 2013).
The core of the brown module, which reflects methylomic differ-
ences related to an individual’s number of education years and
differences in MCI relative to CTL, was shown to be involved in
transmembrane processes (GO), as well as oxytocin signaling
(KEGG). The oxytocin signaling pathway is linked to social behav-
iors, as well as several psychiatric disorders (e.g., depression)
(Feldman et al., 2016) Interestingly, a DMR was recently identified
in the oxytocin gene (OXT), which was hypomethylated in AD brain
(Lardenoije et al., 2019; Watson et al., 2016) and hypermethylated
in the blood in individuals who subsequently converted to AD
(Lardenoije et al., 2019). Oxytocin is involved in the modulation of
stress, social behaviors, and associative learning (Olff et al., 2013),
and altered levels of oxytocin have been reported in AD postmor-
tem brain tissue (Mazurek et al., 1987) and cerebrospinal fluid
(North et al., 1992). It is interesting that the sphingolipid signaling
pathway is found in the KEGG results from the core probes of the
yellowmodule related to differences inMCI relative to CTL. Multiple
studies have indicated that sphingolipid signaling pathways are
implicated in AD (Crivelli et al., 2020), and the measurement of
lipids in the pathway is being explored as a potential biomarker of
AD and neurodegeneration (Mielke and Lyketsos, 2010). Similar to
the cyan module, the majority of GO terms in the core of the yellow
module are related to various processes of immune activation. In
our network analysis examining conversion from MCI to AD, we
identified a pathway in the orange module associated with
nonhomologous end-joining. Nonhomologous end-joining activity
is involved in repairing the double-strand DNA breaks and has been
reported to be decreased in AD brain (Kanungo, 2013; Shackelford,
2006).
In summary, this is the first EWAS to identify epigenetic signa-
tures and functional pathways specific to MCI, AD, and conversion
to AD in the blood. However, there are some limitations to our
study. First, we have profiled DNA methylation patterns in wholeblood, and it is known that there are subtle alterations in the
abundance of specific blood cell types in MCI and AD (Lunnon et al.,
2012). Although we have controlled for the proportions of these
different cells, it will be of interest to investigate disease-associated
signatures in individual cell types. Second, individuals were only
followed up clinically for up to 2 years following the baseline
assessment and further studies should profile cohorts consisting of
CTL and MCI subjects with long-term clinical follow-up to identify
the preclinical changes. In addition, biomarkers were not available
to support the clinical diagnosis of AD. Third, our comparisons of
DNA methylation and gene expression were limited to only those
genes with variable expression levels in the previous study (Lunnon
et al., 2012) and did not examine transcript variants. Fourth, we
have not replicated our findings in an independent study cohort.
Although we did validate our HOXB6 DMR in the same samples
using an alternative technology, in the future it will be interesting
to verify the loci we identified in a different set of samples. Finally,
although there is some communication between the brain and the
blood, not all differences found to be associated with AD in the
blood may be functionally related to the processes taking place in
the brain. Differences in DNA methylation may be the result of
parallel effects or comorbidities, and may not be causally related to
disease, but could reflect mediating or downstream effects. It would
be interesting for future studies to explore the exact role of the
epigenetic signatures identified in this study, and to explore their
potential as biomarkers for an early diagnosis of AD and therapeutic
targets.
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